<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-3-3</article-id><article-id pub-id-type="pmid">12028593</article-id><article-id pub-id-type="doi">10.1186/1471-2350-3-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>PTPRC</italic> (CD45) is not associated with multiple sclerosis in a large cohort of German patients</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Miterski</surname><given-names>Bianca</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bianca.miterski@ruhr-uni-bochum.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Sindern</surname><given-names>Eckhart</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>eckhart.sindern@ruhr-uni-bochum.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Haupts</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>michael.haupts@ruhr-uni-bochum.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Schimrigk</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>sebastian.k.schimrigk@ruhr-uni-bochum.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Epplen</surname><given-names>Joerg T</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>joerg.t.epplen@ruhr-uni-bochum.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Molecular Human Genetics, Ruhr-University, 44780 Bochum, Germany</aff><aff id="I2"><label>2</label>Departments of Neurology, Kliniken Bergmannsheil, Ruhr-University, Bochum, Germany</aff><aff id="I3"><label>3</label>Knappschaftskrankenhaus, Ruhr-University, Bochum, Germany</aff><aff id="I4"><label>4</label>St. Josef-Hospital, Ruhr-University, Bochum, Germany</aff><pub-date pub-type="collection"><year>2002</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2002</year></pub-date><volume>3</volume><fpage>3</fpage><lpage>3</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/3/3"/><history><date date-type="received"><day>7</day><month>2</month><year>2002</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2002</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2002 Miterski et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2002</copyright-year><copyright-holder>Miterski et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title>Background</title><p>Since contradictory results have been reported, we reanalysed the 77C&#x02192;G transition in exon 4 of the protein-tyrosine phosphatase receptor-type C (<italic>PTPRC</italic> also known as CD45) in a large cohort of German MS patients and controls. Different isoforms of the protein are expressed, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (CD45RO, exons 4&#x02013;6 spliced out). The 77C&#x02192;G transition does not change the amino acid sequence, but it is probably part of a motif necessary for splicing leading to the isoform CD45RA. The expression of CD45RA is increased in 77C/G heterozygous individuals. The aim of the study was to clarify the importance of the <italic>PTPRC</italic> 77C&#x02192;G transition in our German cohort of MS patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>PCR products of exon 4 were digested using endonuclease <italic>Msp</italic>I. The resulting restriction fragments of the wildtype C allele are 198 and 62 bp in length. In the G allele an additional restriction site is present yielding fragments of 114 and 84 bp.</p></sec><sec><title>Results</title><p>The G allele was identified in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients (0.8%; Table 1). No homozygous individuals were found either in the control or in the patient group. Genetic association between the <italic>PTPRC</italic> 77C&#x02192;G transition and MS susceptibility was excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical course of MS or according to <italic>HLA-DRB1*15</italic> status did not yield significant differences.</p></sec><sec><title>Conclusions</title><p>The 77C&#x02192;G transition in exon 4 of the <italic>PTPRC</italic> gene may contribute to MS susceptibility only in very few families, if at all, but it is not relevant for the majority of MS cases, including virtually all German patients.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system by demyelination. Both environmental and genetic components contribute to the development of MS. An efficient strategy to elucidate the genetic background of MS is to analyse single nucleotide polymorphisms (SNPs) in respective candidate genes. Since contradictory results have been reported recently [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>], we analysed the 77C&#x02192;G transition in exon 4 of the protein-tyrosine phosphatase receptor-type C (<italic>PTPRC</italic> also known as CD45) [<xref ref-type="bibr" rid="B4">4</xref>]. <italic>PTPRC</italic> is localized on chromosome 1q31-q32 and consists of 35 exons. The gene encodes a 180&#x02013;220 kDa glycoprotein expressed on leukocytes and hematopoietic progenitors [<xref ref-type="bibr" rid="B4">4</xref>]. This receptor is involved in T and B cell activation and in signal transduction by regulating protein-tyrosine kinases. Because of this involvement in immunological reactions, the gene is a candidate for MS predisposition. The protein exists in multiple isoforms, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (CD45RO, exon 4&#x02013;6 spliced out). The 77C&#x02192;G transition does not change the amino acid sequence, but it is probably part of a motif necessary for splicing of CD45RA. The expression of CD45RA is increased in 77C/G heterozygous individuals [<xref ref-type="bibr" rid="B1">1</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Allele frequency of the 77C&#x02192;G transition in <italic>PTPRC.</italic> Homozygosity was not observed.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">C allele (%)</td><td align="left">G allele (%)</td></tr></thead><tbody><tr><td align="left">Controls (N = 347)</td><td align="left">684 (98.6)</td><td align="left">10 (1.4)</td></tr><tr><td align="left">MS patients (N = 454)</td><td align="left">901 (99.2)</td><td align="left">7 (0.8)<sup>*</sup></td></tr><tr><td align="left">RRMS (N = 219)</td><td align="left">435 (99.3)</td><td align="left">3 (0.7)</td></tr><tr><td align="left">SPMS (N = 92)</td><td align="left">182 (98.9)</td><td align="left">2 (1.1)</td></tr><tr><td align="left">PPMS (N = 70)</td><td align="left">139 (99.3)</td><td align="left">1 (0.7)</td></tr><tr><td align="left"><italic>HLA-DRB1<sup>*</sup>15</italic> MS patients (N = 161)</td><td align="left">320 (99.4)</td><td align="left">2 (0.6)</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup> p = 0.2. RRMS = relapsing remitting course of MS; SPMS = secondary progressive course of MS; PPMS = primary progressive course of MS</p></table-wrap-foot></table-wrap></sec><sec sec-type="methods"><title>Methods</title><p>Peripheral blood samples from more than 400 healthy blood donors were obtained with their informed consent, and provided by the department of transplantation and immunology of the University Hospital Eppendorf (Hamburg, Germany). The mean age of the healthy donors was 39.3 &#x000b1; 11.47 years. The male/female ratio was 1.4 &#x000b1; 0.5. More than 800 unrelated MS patients attending the Department of Neurology, University clinics of Bochum and G&#x000f6;ttingen (Germany) participated in this study. The male/female ratio was 1.7 &#x000b1; 0.47, the mean age at MS onset was 29.9 &#x000b1; 9.63 years. 55.3% of all clinically diagnosed MS patients exhibited a relapsing/remitting course of MS (RRMS), 25.8% developed secondary progressive MS (SPMS) and 18.9% were characterized by primary progressive MS (PPMS). The mean EDSS (expanded disability status scale) of all MS patients was 4.2 &#x000b1; 2.31, of PPMS 5.8 &#x000b1; 1.91 and of RRMS+SPMS 3.9 &#x000b1; 2.25 [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Polymerase chain reaction (PCR) of exon 4 of <italic>PTPRC</italic> was carried out in a final volume of 12.5 &#x003bc;l with 50 ng of DNA, 200 &#x003bc;M dNTP, 1 U Taq Polymerase and <italic>PTPRC</italic> exon 4 specific primers (forward, 5'-ATTTATTTTGTCCTTCTCCCA-3' and reverse, 5'-GTTAACAACTTTTGTGTGCCAAC-3'). PCR cycling started with initial denaturation for 5 minutes at 94&#x000b0;C. The annealing temperature of the first cycle was 61&#x000b0;C, second cycle 58&#x000b0;C and remaining 26 cycles 55&#x000b0;C. The annealing time was 1 minute. Extension was performed at 72&#x000b0;C for 1 minute (final extension 5 minutes). PCR products were digested using endonuclease <italic>Msp</italic>I according to the manufacturer's recommendation. Digested DNA was electrophoresed on 1.5% agarose gels. The restriction fragments of the wildtype C allele were 198 and 62 bp in length. The G allele harbors an additional restriction site so that the 198 bp fragment is digested into 114 and 84 bp (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Restriction fragment length polymorphism (RFLP) analysis of <italic>PTPRC</italic> exon 4 77C&#x02192;G; M=pUC19 DNA marker (501, 489, 404, 331, 242, 190, 147, 111, 110, 67 bp)</p></caption><graphic xlink:href="1471-2350-3-3-1"/></fig></sec><sec><title>Results</title><p>The rare G allele was present in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients (0.8%; Table <xref ref-type="table" rid="T1">1</xref>). There were no homozygous individuals either in the control or patient groups. Genetic association between the <italic>PTPRC</italic> 77C&#x02192;G transition and MS susceptibility was excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical course of MS (RRMS, SPMS, PPMS) or according to <italic>HLA-DRB1*15</italic> status did not yield significant differences.</p></sec><sec><title>Discussion</title><p>This result contradicts the findings of Jacobsen <italic>et al.</italic>[<xref ref-type="bibr" rid="B1">1</xref>] who demonstrated an association of the mutation with MS in 3 families. Barcellos <italic>et al.</italic>[<xref ref-type="bibr" rid="B2">2</xref>] and Vorechovsky <italic>et al</italic>. [<xref ref-type="bibr" rid="B3">3</xref>] excluded MS association as well. However, as yet unknown polymorphisms in the <italic>PTPRC</italic> gene may contribute to MS susceptibility.</p></sec><sec><title>Conclusions</title><p>In conclusion, the <italic>PTPRC</italic> exon 4 77C&#x02192;G transition seems to contribute to MS susceptibility only in a few families, if at all, but it is not relevant for the majority of MS cases, also not in virtually all German patients.</p></sec><sec><title>Competing interests</title><p>None declared.</p></sec><sec><title>Authors' contributions</title><p>BM carried out the molecular analyses, ES, MH, and SS examined the MS patients, and JE participated in the study design and the coordination.</p><p>All authors have read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/3/3/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We would like to thank the MS patients for participating in this study, Susann Schiwy, Gudrun Rodepeter and Margret Schumacher for excellent technical assistance and Professor David Ballantyne for his expert corrections of the scientific English. This work was supported by BMBF (01GG9841).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>M</given-names></name><name><surname>Schweer</surname><given-names>D</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name><name><surname>Gaber</surname><given-names>R</given-names></name><name><surname>Schock</surname><given-names>S</given-names></name><name><surname>Schwinzer</surname><given-names>R</given-names></name><name><surname>Wonigeit</surname><given-names>K</given-names></name><name><surname>Lindert</surname><given-names>R-B</given-names></name><name><surname>Kantarci</surname><given-names>O</given-names></name><name><surname>Schaefer-Klein</surname><given-names>J</given-names></name><name><surname>Schipper</surname><given-names>HI</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Heidenreich</surname><given-names>F</given-names></name><name><surname>Weinshenker</surname><given-names>BG</given-names></name><name><surname>Sommer</surname><given-names>N</given-names></name><name><surname>Hemmer</surname><given-names>B</given-names></name></person-group><article-title>A point mutation in <italic>PTPRC</italic> is associated with the development of multiple sclerosis.</article-title><source>Nat Genet</source><year>2000</year><volume>26</volume><fpage>495</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">11101853</pub-id><pub-id pub-id-type="doi">10.1038/82659</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barcellos</surname><given-names>LF</given-names></name><name><surname>Caillier</surname><given-names>S</given-names></name><name><surname>Dragone</surname><given-names>L</given-names></name><name><surname>Elder</surname><given-names>M</given-names></name><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Bucher</surname><given-names>P</given-names></name><name><surname>Lincoln</surname><given-names>RR</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Hauser</surname><given-names>SL</given-names></name><name><surname>Oksenberg</surname><given-names>JR</given-names></name></person-group><article-title><italic>PTPRC</italic> (CD45) is not associated with the development of multiple sclerosis in U.S. patients.</article-title><source>Nat Genet</source><year>2001</year><volume>29</volume><fpage>2323</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/ng722</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vorechovsky</surname><given-names>I</given-names></name><name><surname>Kralovicova</surname><given-names>J</given-names></name><name><surname>Tchilian</surname><given-names>E</given-names></name><name><surname>Masterman</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Ferry</surname><given-names>B</given-names></name><name><surname>Misbah</surname><given-names>S</given-names></name><name><surname>Chapel</surname><given-names>H</given-names></name><name><surname>Webster</surname><given-names>D</given-names></name><name><surname>Hellgren</surname><given-names>D</given-names></name><name><surname>Anvret</surname><given-names>M</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><name><surname>Hammarstrom</surname><given-names>L</given-names></name><name><surname>Beverley</surname><given-names>PC</given-names></name></person-group><article-title>Does 77C&#x02192;G in <italic>PTPRC</italic> modify autoimmune disorders linked to the major histocompatibility locus?</article-title><source>Nat Genet</source><year>2001</year><volume>29</volume><fpage>22</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11548742</pub-id><pub-id pub-id-type="doi">10.1038/ng723</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thude</surname><given-names>H</given-names></name><name><surname>Hundrieser</surname><given-names>J</given-names></name><name><surname>Wonigeit</surname><given-names>K</given-names></name><name><surname>Schwinzer</surname><given-names>R</given-names></name></person-group><article-title>A point mutation in the human CD45 gene associated with defective splicing of exon A.</article-title><source>Eur J Immunol</source><year>1995</year><volume>25</volume><fpage>2101</fpage><lpage>2106</lpage><pub-id pub-id-type="pmid">7621884</pub-id></citation></ref><ref id="B5"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Miterski</surname><given-names>B</given-names></name><name><surname>B&#x000f6;hringer</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>W</given-names></name><name><surname>Sindern</surname><given-names>E</given-names></name><name><surname>Haupts</surname><given-names>M</given-names></name><name><surname>Schimrigk</surname><given-names>S</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name></person-group><article-title>Inhibitors in the NF&#x003ba;B cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations.</article-title><source>Genes and Immunity</source><year>2002</year><comment></comment></citation></ref></ref-list></back></article> 